Kate Bingham, managing partner at SV Life Sciences, says that biologics are "hot" right now for investors. Speaking at a European conference, Bingham said that deal-making [1]Â and greater innovation were driving the growth of the continent's biotech sector. "Innovation is being concentrated on drugs being prescribed by specialists in hospitals," she told the group, with antibodies [2]Â also attracting a lot of attention.
- read the report [3] from AFX
Related Articles:
MAbs are hottest segment of biotech industry. Report [2]
Sanofi: We're looking for biotech deals. Report [4]
Pfizer's future rests with biotech. Report [5]
Lines blur as Big Pharma crosses borders into biotech. Report [1]
Links:
[1] http://www.fiercebiotech.com/story/lines-blur-as-big-pharma-crosses-borders-into-biotech/2007-05-30
[2] http://www.fiercebiotech.com/story/mabs-are-hottest-segment-biotech-industry/2007-10-12
[3] http://www.iii.co.uk/news/?type=afxnews&articleid=6426203&action=article
[4] http://www.fiercebiotech.com/story/sanofi-were-looking-biotech-deals/2007-11-30
[5] http://www.fiercebiotech.com/story/pfizers-future-rests-biotech/2007-09-13?utm_medium=nl&utm_source=internal